drugset / Trial / NCT05261269
A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
This was an open-label, multicenter, dose-escalation study designed to assess the safety, tolerability, and PK of IV administered DAN-222 followed by a dose-escalation of DAN-222 in combination with niraparib: * Part A is dose escalation of single agent DAN-222 * Part B is dose escalation of DAN-222 in combination with niraparib
Timeline
- Start
- 2022-02-02
- Primary completion
- 2023-09-13
- Completion
- 2023-10-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DAN222 | Unknown | — | Intravenous |
| Background | Niraparib | Small molecule | — | Oral |